Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Growth hormone study aims to improve body composition in Prader-Willi syndrome

NCT ID NCT04697381

First seen Jan 16, 2026 · Last updated May 23, 2026 · Updated 16 times

Summary

This study tested the safety and effectiveness of somatropin, a growth hormone, in 33 Japanese people with Prader-Willi syndrome. The goal was to see if the treatment could improve lean body mass (muscle) over 12 months. Participants included both children and adults, and the study is now complete.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRADER-WILLI SYNDROME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Dokkyo Medical University Saitama Medical Center

    Koshigaya, Saitama, 343-8555, Japan

  • Hamamatsu University Hospital

    Hamamatsu, Shizuoka, 431-3192, Japan

  • Kanagawa Children's Medical Center

    Yokohama, Kanagawa, 232-8555, Japan

  • National Center for Child Health and Development

    Setagaya-ku, Tokyo, 157-8535, Japan

  • Osaka Women's and Children's Hospital

    Izumi, Osaka, 594-1101, Japan

Conditions

Explore the condition pages connected to this study.